EP0950044A1 - Preparation of gabapentin - Google Patents

Preparation of gabapentin

Info

Publication number
EP0950044A1
EP0950044A1 EP97954134A EP97954134A EP0950044A1 EP 0950044 A1 EP0950044 A1 EP 0950044A1 EP 97954134 A EP97954134 A EP 97954134A EP 97954134 A EP97954134 A EP 97954134A EP 0950044 A1 EP0950044 A1 EP 0950044A1
Authority
EP
European Patent Office
Prior art keywords
gabapentin
solvent
butanol
hydrochloride
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97954134A
Other languages
German (de)
French (fr)
Other versions
EP0950044A4 (en
Inventor
Michael Pesachovich
Claude Singer
Gideon Pilarski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP0950044A1 publication Critical patent/EP0950044A1/en
Publication of EP0950044A4 publication Critical patent/EP0950044A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • This invention relates to a new process for converting gabapentin hydrochloride salt to gabapentin via a novel polymorphic form of gabapentin.
  • Gabapentin is 1- (aminomethyl) -1-cyclohexaneacetic acid, having the chemical structure:
  • Gabapentin is used in the treatment of cerebral diseases such as epilepsy.
  • the literature describes many ways of preparing gabapentin from a variety of starting materials.
  • U.S. Patent 4,024,175 describes at least three methods of preparing gabapentin from cyclohexyl-1, 1-diacetic acid. Each of these methods results in the formation of gabapentin hydrochloride salt, which may be converted to 1- (aminomethyl) -1- cyclohexaneacetic acid by treatment with a basic ion exchanger and then crystallized from a solvent such as ethanol/ether .
  • U.S. Patent 4,894,476 specifically discloses an improved method for converting the hydrochloride salt into the free amino acid. This involves pouring a deionized water solution of the salt over an ion exchange column, eluting with deionized water, producing a slurry from the eluate, adding an alcohol to the slurry, centrifuging and drying the slurry to obtain the free amino acid.
  • gabapentin is crystalline and exhibits an X-ray diffraction pattern with peaks of 2-theta values at 7.8, 13.3, 15.0, 17.0, 20.4, 21.3, 23.1, 23.6, 25.7, 27.0 and 28.2 degrees.
  • polymorph form "II" the commercially available polymorphic form of gabapentin is referred to as polymorph form "II".
  • the present invention relates to an improved method for purifying gabapentin comprising converting gabapentin hydrochloride salt to gabapentin form II.
  • the present invention avoids the disadvantages associated with prior art methods, by adding alternative steps and by proceeding via a novel polymorphic form of gabapentin.
  • the present invention relates to a method of converting gabapentin hydrochloride salt to gabapentin form II, comprising reacting a solution of gabapentin hydrochloride with an additional amine in a first solvent to produce a novel polymorphic form as a precipitate, thereafter, converting the novel polymorphic form to form II by forming a suspension and/or a solution of the precipitate in methanol, and then recovering gabapentin form II.
  • the present invention further relates to a novel polymorphic form of gabapentin designated as gabapentin form III.
  • the polymorph may be identified by its unique X-ray diffraction pattern.
  • a further aspect of the present invention relates to the novel polymorphic form of gabapentin that is of use as an intermediate in the preparation of polymorphic form II.
  • Fig. 1 is an x-ray diffraction pattern of a sample of gabapentin hydrate.
  • Fig. 2 is an x-ray diffraction pattern of gabapentin form II.
  • Figs. 3a and 3b are x-ray diffraction pattern of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
  • Fig. 4 is an FTIR (Fourier Transform Infra Red) spectrum of gabapentin hydrate.
  • Fig. 5 is an FTIR spectrum of gabapentin form II.
  • Fig. 6 is an FTIR spectrum of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
  • the method of the present invention comprises:
  • the gabapentin hydrochloride used as a starting material in the process of the present invention is substantially free of other inorganic salts such as sodium chloride and sodium bromide, that is, such impurities are only present in trace amounts.
  • gabapentin hydrochloride containing inorganic salts may be used subject to the addition of a further step for removing the inorganic salts prior to mixing gabapentin hydrochloride with the additional amine.
  • gabapentin hydrochloride containing inorganic salts may optionally be pre-treated to remove the inorganic salts by the steps of (a) dissolution in a solvent in which gabapentin hydrochloride is soluble, but the inorganic salts are not; (b) filtration of the inorganic salts and, optionally, (c) evaporating the solvent to recover gabapentin hydrochloride substantially free of inorganic salts.
  • Appropriate solvents for the optional pre-treatment step include those selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide.
  • the pre-treatment solvent is identical to the first solvent.
  • This pre-treatment solvent which is identified in Table 1 and in the claims as the "second solvent”, would be used prior to using the "first solvent", if, in fact, this optional pre-treament step is included in the process.
  • the second step of the present invention comprises mixing a solution of the gabapentin hydrochloride in a solvent that contains an additional amine.
  • the solvent may be any solvent in which the hydrochloride salt of the additional amine is soluble but in which gabapentin form III is insoluble, such that a precipitate of gabapentin form III is formed.
  • Such solvents are preferably selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
  • the precipitated gabapentin which may be separated by filtration, is characterized herein as a novel polymorphic form of gabapentin, possessing a crystalline structure characterized by peaks in the powder X ray diffraction pattern with 2-theta values at 6.11, 12.22, 17.00, 18.20, 19.94, 20.81, 24.54, and 25.11 degrees, all ⁇ 0.2 degrees.
  • the x-ray diffraction pattern in the samples obtained appears to show a preferred orientation in which the peak at 6.11 degrees is larger than any other peak in the pattern, and the peaks at 12.22 and 24.54 degrees are larger than any of the remaining peaks in the pattern.
  • This polymorph is referred to herein as gabapentin form III.
  • Slurrying may be performed by suspending the precipitated gabapentin in methanol by mixing, stirring, and/or providing continuous agitation with some mechanical device so as to induce transformation into the gabapentin form II that is the commercially available polymorphic form of gabapentin. Gabapentin form II may then be filtered off and washed.
  • the precipitated gabapentin may be crystallized from methanol with heating by reflux until dissolved, cooling, optionally seeding with gabapentin, followed by further cooling, and then collecting and drying the crystals of gabapentin form II. Second and multiple crops may be obtained from the concentrated mother liqueurs.
  • Suitable amines for use in the present invention include triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine.
  • the amine is tributylamine.
  • the form II gabapentin obtained by the methods of the present invention may be crystallized using processes known in the art.
  • Gabapentin hydrochloride containing inorganic salts NaCl, NaBr
  • inorganic salts NaCl, NaBr
  • Example 4 Variant A was dissolved in 150 ml isopropanol and mixed at 25°C. Active carbon (0.9 g) was added and the suspension mixed for a further 2 hours. The inorganic salts were removed by filtering. The filter cake was washed twice with 15 ml isopropanol and the washings were added to the gabapentin hydrochloride solution.
  • the still humid filter cake from step 2 was suspended in 210 ml of methanol and the suspension was heated to reflux (65°C) . If dissolution was incomplete, additional methanol was added.
  • the reactor content was cooled to 34°C at which temperature crystallization was induced by seeding with pure Form II gabapentin base (0.1 g) .
  • the reactor content was cooled to 25°C and methanol was distilled by vacuum distillation. Approximately 160 ml of methanol was collected. Then the suspension was cooled to 0-10°C and maintained at this temperature for 2 hours .
  • the crystalline gabapentin was separated by filtration from the suspension.
  • the filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g of crystalline gabapentin form II (yield 72%) was thus obtained.
  • Example 2-20 The method of Example 1 was followed using the slurrying technique of step C(l) and employing the amines and solvents shown in Table 1 below. The percent yields are of purified product except where marked with an asterisk (*) , where the yield was measured at the stage prior to the slurrying in methanol. Table 1. Summary of the first solvent, second solvent, amine and yield of examples 2-20.
  • IPA isopropanol MEK methyl ethyl ketone ACN acetonitrile EGMME ethyleneglycol monomethylether BzOH benzyl alcohol TBA tributylamine MeOH methanol BzA benzylamine CH 2 C1 2 methylene chloride IPA Ac isopropylacetate THA trihexylamine DMC dimethylcarbonate TPA tripropylamine (t)-BuOH (tert) -butanol Et Ac ethyl acetate TEA triethylamine DMA dimethylacetamide DEA diethylamine
  • the gabapentin form III was characterized by comparing the x- ray diffraction pattern and the FTIR absorption spectra of gabapentin form III with gabapentin form II and gabapentin hydrate.
  • the x-ray powder diffraction patterns of Figures 1, 2, and 3a were obtained using a Philips x-ray powder diffractometer with the following parameters:
  • Type of radiation copper K .
  • Figure 3b was obtained using a Siemens B5100 with a presample (K ⁇ ! only) monochromator, step scan, Cu radiation, beam slits 0.3, receiving slit 0.05, standard Siemens rotating sample holder, start/stop/step angles in degrees were 4.0, 35, and 0.04, with a step duration of 15 seconds.
  • Standard Siemens D- 5000 software was used.
  • the diffractometer was calibrated with NIST large d-spacing standard. No theta-compensating slits were employed.
  • Figs. 1-3 The x-ray spectra of gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 1-3, respectively.
  • the main diffraction peaks that characterize each material are listed in Table 2.
  • FTIR spectra for gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 4-6, respectively.
  • the FTIR peaks are summarized in Table 3,
  • the hydrate form typically exists as large crystals with undefined shapes.
  • Form II typically exists as plate shaped crystals.
  • Form III typically exists as small rhomboidal crystals.
  • the melting point for gabapentin was not determined since gabapentin decomposes prior to melting.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

There is disclosed a method of converting gabapenting hydrochloride substantially free of inorganic salts to gabapenting form II. The method comprises the steps of: (1) obtaining gabapentin hydrochloride that is substantially free of inorganic salts; (2) mixing a solution of the gabapenting hydrochloride with an additional amine in a first solvent so as to obtain a precipitate comprising gabapenting; and then (3) recovering gabapentin form II from the precipitate. The precipitated gabapentin is a novel polymorphic form of gabapentin possessing a crystalline structure characterized by novel sets of peaks in the powder X-ray diffraction pattern and in the FTIR spectra. This newly disclosed polymorph of gabapentin is characterized herein as gabapentin form III. The recovery step may comprise, for example, one of two alternative methods, slurrying the gabapentin form II in methanol, and then filtering the suspension to obtain gabapentin form II, or solubilizing the gabapentin form III in methanol with heating by reflux, and then cooling the solution to obtain gabapentin form II by crystallization.

Description

PREPARATION OF GABAPENTIN
FIELD OF THE INVENTION
This invention relates to a new process for converting gabapentin hydrochloride salt to gabapentin via a novel polymorphic form of gabapentin.
BACKGROUND OF THE INVENTION
Gabapentin is 1- (aminomethyl) -1-cyclohexaneacetic acid, having the chemical structure:
Gabapentin is used in the treatment of cerebral diseases such as epilepsy. The literature describes many ways of preparing gabapentin from a variety of starting materials. U.S. Patent 4,024,175 describes at least three methods of preparing gabapentin from cyclohexyl-1, 1-diacetic acid. Each of these methods results in the formation of gabapentin hydrochloride salt, which may be converted to 1- (aminomethyl) -1- cyclohexaneacetic acid by treatment with a basic ion exchanger and then crystallized from a solvent such as ethanol/ether .
U.S. Patent 4,894,476 specifically discloses an improved method for converting the hydrochloride salt into the free amino acid. This involves pouring a deionized water solution of the salt over an ion exchange column, eluting with deionized water, producing a slurry from the eluate, adding an alcohol to the slurry, centrifuging and drying the slurry to obtain the free amino acid.
Alternative methods for preparing gabapentin have been described that do not proceed via the hydrochloride or any other mineral acid salt. Such methods include those described in U.S. Patent Nos. 5,132,451, 5,095,148, 5,068,413. Each of these methods involve a cyanic intermediate which is hydrogenated under severe conditions to produce the free amino acid.
These methods are industrially impractical. Those methods comprising ion exchange columns require the use of large amounts of ion exchanger for lengthy periods of time to lower the level of chloride ions to the desired level. The alternative methods involve further more demanding steps.
Commercially available gabapentin is crystalline and exhibits an X-ray diffraction pattern with peaks of 2-theta values at 7.8, 13.3, 15.0, 17.0, 20.4, 21.3, 23.1, 23.6, 25.7, 27.0 and 28.2 degrees. Hereinafter, the commercially available polymorphic form of gabapentin is referred to as polymorph form "II".
SUMMARY OF THE INVENTION
The present invention relates to an improved method for purifying gabapentin comprising converting gabapentin hydrochloride salt to gabapentin form II. The present invention avoids the disadvantages associated with prior art methods, by adding alternative steps and by proceeding via a novel polymorphic form of gabapentin.
Accordingly, the present invention relates to a method of converting gabapentin hydrochloride salt to gabapentin form II, comprising reacting a solution of gabapentin hydrochloride with an additional amine in a first solvent to produce a novel polymorphic form as a precipitate, thereafter, converting the novel polymorphic form to form II by forming a suspension and/or a solution of the precipitate in methanol, and then recovering gabapentin form II.
The present invention further relates to a novel polymorphic form of gabapentin designated as gabapentin form III. The polymorph may be identified by its unique X-ray diffraction pattern.
A further aspect of the present invention relates to the novel polymorphic form of gabapentin that is of use as an intermediate in the preparation of polymorphic form II.
Further objectives and advantages of the subject invention will be apparent to those skilled in the art from the detailed description of the disclosed invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an x-ray diffraction pattern of a sample of gabapentin hydrate.
Fig. 2 is an x-ray diffraction pattern of gabapentin form II.
Figs. 3a and 3b are x-ray diffraction pattern of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
Fig. 4 is an FTIR (Fourier Transform Infra Red) spectrum of gabapentin hydrate.
Fig. 5 is an FTIR spectrum of gabapentin form II.
Fig. 6 is an FTIR spectrum of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The subject invention will now be described in detail for specific preferred embodiments of the invention, it being understood that these embodiments are intended only as illustrative examples and the invention is not to be limited thereto.
The method of the present invention comprises:
(1) obtaining gabapentin hydrochloride that is substantially free of inorganic salts;
(2) mixing a solution of the gabapentin hydrochloride with an additional amine in a first solvent so as to obtain a precipitate comprising gabapentin; and then
(3) recovering gabapentin form II from the precipitate.
Preferably, the gabapentin hydrochloride used as a starting material in the process of the present invention is substantially free of other inorganic salts such as sodium chloride and sodium bromide, that is, such impurities are only present in trace amounts. Alternatively, gabapentin hydrochloride containing inorganic salts may be used subject to the addition of a further step for removing the inorganic salts prior to mixing gabapentin hydrochloride with the additional amine.
Thus, gabapentin hydrochloride containing inorganic salts may optionally be pre-treated to remove the inorganic salts by the steps of (a) dissolution in a solvent in which gabapentin hydrochloride is soluble, but the inorganic salts are not; (b) filtration of the inorganic salts and, optionally, (c) evaporating the solvent to recover gabapentin hydrochloride substantially free of inorganic salts. Appropriate solvents for the optional pre-treatment step include those selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide. Preferably the pre-treatment solvent is identical to the first solvent. This pre-treatment solvent, which is identified in Table 1 and in the claims as the "second solvent", would be used prior to using the "first solvent", if, in fact, this optional pre-treament step is included in the process.
The second step of the present invention comprises mixing a solution of the gabapentin hydrochloride in a solvent that contains an additional amine. The solvent may be any solvent in which the hydrochloride salt of the additional amine is soluble but in which gabapentin form III is insoluble, such that a precipitate of gabapentin form III is formed. Such solvents are preferably selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide. The precipitated gabapentin, which may be separated by filtration, is characterized herein as a novel polymorphic form of gabapentin, possessing a crystalline structure characterized by peaks in the powder X ray diffraction pattern with 2-theta values at 6.11, 12.22, 17.00, 18.20, 19.94, 20.81, 24.54, and 25.11 degrees, all ±0.2 degrees. The x-ray diffraction pattern in the samples obtained appears to show a preferred orientation in which the peak at 6.11 degrees is larger than any other peak in the pattern, and the peaks at 12.22 and 24.54 degrees are larger than any of the remaining peaks in the pattern. This polymorph is referred to herein as gabapentin form III. Two representative embodiments of the third step of the present invention, recovery of gabapentin form II from the precipitate, are slurrying and crystallization. Slurrying may be performed by suspending the precipitated gabapentin in methanol by mixing, stirring, and/or providing continuous agitation with some mechanical device so as to induce transformation into the gabapentin form II that is the commercially available polymorphic form of gabapentin. Gabapentin form II may then be filtered off and washed.
Alternatively, the precipitated gabapentin may be crystallized from methanol with heating by reflux until dissolved, cooling, optionally seeding with gabapentin, followed by further cooling, and then collecting and drying the crystals of gabapentin form II. Second and multiple crops may be obtained from the concentrated mother liqueurs.
Suitable amines for use in the present invention include triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine. Preferably the amine is tributylamine.
The form II gabapentin obtained by the methods of the present invention may be crystallized using processes known in the art.
Certain specific representative embodiments of the invention are described in detail below, the materials, apparatus and process steps being understood as examples that are intended to be exemplary and illustrative only. In particular, the invention is not intended to be limited to the methods, materials, conditions, process parameters, apparatus and the like specifically recited herein.
EXAMPLES 1. Preparation of gabapentin from gabapentin hydrochloride
A. Removal of Inorganic Salts
Gabapentin hydrochloride containing inorganic salts (NaCl, NaBr) , which may be prepared, for example, as shown in U.S.
Pat. No. 4,024,175, Example 4, Variant A, was dissolved in 150 ml isopropanol and mixed at 25°C. Active carbon (0.9 g) was added and the suspension mixed for a further 2 hours. The inorganic salts were removed by filtering. The filter cake was washed twice with 15 ml isopropanol and the washings were added to the gabapentin hydrochloride solution.
B. Precipitation of Gabapentin Base; Formation of Gabapentin Form III The gabapentin hydrochloride solution of part A was concentrated to dryness in vacuum while ensuring that the temperature of the heating bath did not exceed 35°C. 210 ml ethylacetate and 16.5 ml tributylamine were added and the solution was mixed for 2 hours at 25°C. The gabapentin precipitate was then separated by filtration, the filter cake being washed with 20 ml ethylacetate and then 20 ml methanol. The filter cake contained gabapentin form III which when dried displayed a characteristic X-ray diffraction pattern with 2- theta values at 6.1, 12.2, 17.0, 17.7, 18.3, 20.0, 20.8, 24.6 and 25.5 degrees.
C. Alternative Methods for Conversion of Precipitated Gabapentin to Gabapentin Form II
(1) Slurrying
The still humid filter cake from step 2 was suspended in 52.5 ml methanol for about 14 hours at 25°C. Solid gabapentin was then separated from the suspension by filtration. The filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g crystalline gabapentin form II (yield 72%) was obtained. (2 ) Crystallization
The still humid filter cake from step 2 was suspended in 210 ml of methanol and the suspension was heated to reflux (65°C) . If dissolution was incomplete, additional methanol was added.
After dissolution, the reactor content was cooled to 34°C at which temperature crystallization was induced by seeding with pure Form II gabapentin base (0.1 g) .
After maintaining the mixture at 34 °C for 60 minutes the reactor content was cooled to 25°C and methanol was distilled by vacuum distillation. Approximately 160 ml of methanol was collected. Then the suspension was cooled to 0-10°C and maintained at this temperature for 2 hours .
The crystalline gabapentin was separated by filtration from the suspension. The filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g of crystalline gabapentin form II (yield 72%) was thus obtained.
Examples 2-20 The method of Example 1 was followed using the slurrying technique of step C(l) and employing the amines and solvents shown in Table 1 below. The percent yields are of purified product except where marked with an asterisk (*) , where the yield was measured at the stage prior to the slurrying in methanol. Table 1. Summary of the first solvent, second solvent, amine and yield of examples 2-20.
IPA isopropanol MEK methyl ethyl ketone ACN acetonitrile EGMME ethyleneglycol monomethylether BzOH benzyl alcohol TBA tributylamine MeOH methanol BzA benzylamine CH2C12 methylene chloride IPA Ac isopropylacetate THA trihexylamine DMC dimethylcarbonate TPA tripropylamine (t)-BuOH (tert) -butanol Et Ac ethyl acetate TEA triethylamine DMA dimethylacetamide DEA diethylamine
The gabapentin form III was characterized by comparing the x- ray diffraction pattern and the FTIR absorption spectra of gabapentin form III with gabapentin form II and gabapentin hydrate. The x-ray powder diffraction patterns of Figures 1, 2, and 3a were obtained using a Philips x-ray powder diffractometer with the following parameters:
Goniometer model 1050/70, Cu-tube, Curved graphite monochromator .
Sample holder: Quartz monocrystal plate Settings :
X-Ray tube: KV-40 mA-28 Target-Cu Divergence slit-l° Receiving parallel slit-0.2 mm Scatter slit-l°
Scintillation detector: Voltage-832 Lower level-33.8% Window-34.5% Scan parameters:
Scanning speed: 2°/min Paper speed: 2cm/min Gain: 32
Calibration: External calibration with silicon fine powder
Type of radiation: copper K .
Figure 3b was obtained using a Siemens B5100 with a presample (Kα! only) monochromator, step scan, Cu radiation, beam slits 0.3, receiving slit 0.05, standard Siemens rotating sample holder, start/stop/step angles in degrees were 4.0, 35, and 0.04, with a step duration of 15 seconds. Standard Siemens D- 5000 software was used. The diffractometer was calibrated with NIST large d-spacing standard. No theta-compensating slits were employed.
The x-ray spectra of gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 1-3, respectively. The main diffraction peaks that characterize each material are listed in Table 2.
Table 2. X-ray Diffraction peaks of gabapentin hydrate, gabapentin form II and gabapentin form III.
The FTIR spectra for gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 4-6, respectively. The FTIR peaks are summarized in Table 3,
Table 3. FTIR peaks of gabapentin hydrate, gabapentin form II and gabapentin form III.
Morphology of the three forms: 1. The hydrate form typically exists as large crystals with undefined shapes.
2. Form II typically exists as plate shaped crystals.
3. Form III typically exists as small rhomboidal crystals.
The melting point for gabapentin was not determined since gabapentin decomposes prior to melting.

Claims

What Is Claimed Is :
1. A method of converting gabapentin hydrochloride to gabapentin form II comprising:
(1) dissolving gabapentin hydrochloride in a first solvent in which gabapentin is relatively insoluble; and
(2) adding an additional amine to the gabapentin hydrochloride solution so as to obtain a precipitate comprising gabapentin.
2. The method of claim 1, further comprising the step of recovering gabapentin form II from said precipitate.
3. The method of claim 2, the recovering step comprising slurrying or crystallizing said precipitate in methanol.
4. The method of claim 3, wherein said first solvent is selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
5. The method of claim 1 wherein said additional amine is selected from the group consisting of triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine.
6. The method of claim 5 wherein said additional amine is tributylamine .
7. The method of claim 1 wherein said first solvent is selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
8. The method of claim 7 wherein said first solvent is ethylacetate.
9. The method of claim 1 wherein said first solvent is one in which the hydrochloride salt of said additional amine is soluble .
10. The method of claim 1 further comprising pre-treating said gabapentin hydrochloride to remove inorganic salts, which pre-treatment comprises (a) dissolving gabapentin hydrochloride in a second solvent in which inorganic salts are insoluble, (b) filtering off the inorganic salts, and (c) recovering gabapentin hydrochloride from said second solvent.
11. The method of claim 10 wherein said second solvent is selected from the group consisting of methanol, ethanol, n- propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide .
12. The method of claim 11 wherein said second solvent is isopropanol .
13. The method of claim 1 or 10 wherein the precipitated gabapentin comprises gabapentin form III.
14. The method of claim 10 wherein the precipitated gabapentin comprises gabapentin form III, said second solvent is isopropanol, said first solvent is ethylacetate, and said additional amine is tributylamine.
15. The method of claim 14 wherein said precipitated gabapentin is slurried or crystallized from methanol to yield gabapentin form II.
16. Crystalline gabapentin form III characterized by powder X-ray diffraction peaks at 6.11+0.2, 12.2210.2, 17.00┬▒0.2, 17.6310.2, 18.20+0.2, 19.9410.2, 20.8110.2, 24.5410.2, 25.11+0.2, 28.9110.2, 30.2010.2, 30.7810.2, and 31.4610.2 degrees 2-theta.
17. Crystalline gabapentin form III characterized by powder X-ray diffraction peaks at 6.1110.2, 12.2210.2, 17.00+0.2, 17.63+0.2, 18.2010.2, 19.9410.2, 20.8110.2, 24.5410.2, 25.1110.2, 28.9110.2, 30.2010.2, 30.7810.2, and 31.4610.2 degrees 2-theta, wherein the size of the peaks is in the order 6.11 degrees > 12.22 and 24.54 > 17.00, 17.63, 18.20, 19.94, 20.81, 25.11, 28.91, 30.20, 30.78, and 31.46.
18. Crystalline gabapentin form III characterized by infra-red absorptions having peaks at 708, 760, 885, 926, 974, 1160, 1180, 1290, 1420, 1460, 1510, 1586, and 1664 cm"1.
19. Crystalline gabapentin form III produceable by a process comprising the steps of:
(a) dissolving gabapentin hydrochloride in a solvent selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide;
(b) adding an additional amine selected from the group consisting of triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine; and
(c) drying the precipitated gabapentin.
EP97954134A 1996-12-24 1997-12-24 Preparation of gabapentin Withdrawn EP0950044A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11989096 1996-12-24
IL11989096A IL119890A (en) 1996-12-24 1996-12-24 Gabapentin form iii and preparation of gabapentin form ii
PCT/US1997/023164 WO1998028255A1 (en) 1996-12-24 1997-12-24 Preparation of gabapentin

Publications (2)

Publication Number Publication Date
EP0950044A1 true EP0950044A1 (en) 1999-10-20
EP0950044A4 EP0950044A4 (en) 2003-03-26

Family

ID=11069615

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97954134A Withdrawn EP0950044A4 (en) 1996-12-24 1997-12-24 Preparation of gabapentin

Country Status (7)

Country Link
EP (1) EP0950044A4 (en)
AU (1) AU5799098A (en)
CA (1) CA2275912A1 (en)
DE (1) DE97954134T1 (en)
ES (1) ES2204362T1 (en)
IL (1) IL119890A (en)
WO (1) WO1998028255A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137137B1 (en) * 1998-05-25 2000-08-16 Medichem Sa NEW POLYMORPH OF UNHYDRATED GABAPENTINE, ITS PROCEDURE FOR OBTAINING AND ITS USE FOR THE OBTAINING OF PHARMACEUTICAL QUALITY GABAPENTINE.
IT1311984B1 (en) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi PROCEDURE FOR THE PREPARATION OF GABAPENTIN.
DK1169060T3 (en) 1999-04-09 2006-01-16 Euro Celtique Sa Sodium channel blocker preparations and their use
ES2164527B1 (en) * 1999-04-26 2003-04-01 Medichen S A PROCEDURE FOR OBTAINING GABAPENTINA OF PHARMACEUTICAL QUALITY.
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
DE60101476T2 (en) * 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. STABLE GABAPENTIN CONTAINING MORE THAN 20 PPM CHLORINE
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
IT1319674B1 (en) * 2000-12-01 2003-10-23 Erregierre Spa PROCESS FOR THE PREPARATION OF CYCLOHEXANACETIC ACID1- (AMINOMETHYL).
MXPA04002009A (en) 2001-09-03 2004-07-08 Newron Pharm Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use.
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
AU2002356424A1 (en) 2002-11-18 2004-06-15 Nicholas Piramal India Limited Improved process for preparation of gabapentin
ES2339756T3 (en) 2002-11-20 2010-05-25 Hikal Ltd. IMPROVED PROCEDURE FOR THE PREPARATION OF AMYNOMETHYLCILLOCANACETIC ACIDS.
US7439387B2 (en) 2003-04-21 2008-10-21 Matrix Laboratories Ltd. Process for the preparation of Gabapentin form-II
WO2004093779A2 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of gabapentin form-ii
WO2004106281A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Crystalline gabapentin
WO2004110342A2 (en) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd Novel polymorph of gabapentin and its conversion to gabapentin form-ii
WO2004110981A1 (en) * 2003-06-12 2004-12-23 Matrix Laboratories Ltd A process for the preparation of gabapentin form-ii
US7169812B2 (en) 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ITMI20040579A1 (en) 2004-03-25 2004-06-25 Zambon Spa GABAPENTINA PREPARATION PROCESS
GB0415076D0 (en) * 2004-07-05 2004-08-04 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
EP2007710A1 (en) * 2007-02-28 2008-12-31 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin by liquid-liquid extraction
EP2183211A1 (en) 2007-07-27 2010-05-12 Medichem, S.A. Method for preparing polymorph form ii of gabapentin
CN102363598B (en) * 2011-11-25 2014-02-12 浙江精进药业有限公司 Method for preparing high-purity gabapentin
ITMI20131757A1 (en) 2013-10-22 2015-04-23 Zach System Spa GABAPENTINE PREPARATION PROCESS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (en) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
DE3928184A1 (en) * 1989-08-25 1991-02-28 Goedecke Ag METHOD FOR PRODUCING CYCLIC AMINO ACID DERIVATIVES AND INTERMEDIATE PRODUCTS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9828255A1 *

Also Published As

Publication number Publication date
EP0950044A4 (en) 2003-03-26
CA2275912A1 (en) 1998-07-02
IL119890A (en) 2002-03-10
AU5799098A (en) 1998-07-17
WO1998028255A1 (en) 1998-07-02
IL119890A0 (en) 1997-03-18
DE97954134T1 (en) 2004-04-15
ES2204362T1 (en) 2004-05-01

Similar Documents

Publication Publication Date Title
US6255526B1 (en) Preparation of gabapentin
WO1998028255A1 (en) Preparation of gabapentin
EP2327708A2 (en) Purification method for adefovir dipivoxil
JPS585904B2 (en) Method for producing guanidine and its salts
RU2586117C2 (en) Crystallisation of epirubicin hydrochloride
CN109836424B (en) Method for preparing caffeine by methylation of environment-friendly theophylline sodium salt
WO2008096373A2 (en) Process for synthesizing highly pure nateglinide polymorphs
CN109689620B (en) Method for resolving baclofen salt
EP0611369A1 (en) Process for preparing (s) (+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)
JP3318992B2 (en) Method for producing N- (α-alkoxyethyl) formamide
KR101287425B1 (en) Preparation of crystalline form II of glyceryl phosphoryl choline
JP2988019B2 (en) Method for producing sodium N-alkylaminoethanesulfonate
KR101287422B1 (en) Crystalline form I of glyceryl phosphoryl choline
JP3042122B2 (en) Method for producing N-cyanoacetamidine derivative
JP3848714B2 (en) Process for producing ethylenediamine-N, N'-disuccinic acid and its ferric complex salt
KR101287423B1 (en) Crystalline form II of glyceryl phosphoryl choline
CN106432197B (en) Ledipasvir intermediate mono-p-toluenesulfonate, crystal form and preparation method thereof
CN113087680A (en) DOTA crystal form and preparation method thereof
JP2942380B2 (en) Method for purifying methacrylamide
JPH10316646A (en) Production of high-purity crystalline o-methyliso urea acetate and crystalline o-methylisourea acetate obtained by the same
JPH1180099A (en) Preparation of (1r,2r)-1-amino-2-indanol-(r,r)-tartrate methanol solvate
WO2006090208A1 (en) Process and methods for the preparation of gabapentin and its intermediates
CN117164464A (en) Crystal form of trientine hydrate and preparation method thereof
JP2770512B2 (en) Method for purifying alkali metal salts of aminoethylsulfonic acid
CN117186163A (en) Sucralose-6-acetate purification process

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990721

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030212

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07C 229/28 B

Ipc: 7C 07C 227/40 A

17Q First examination report despatched

Effective date: 20030318

EL Fr: translation of claims filed
REG Reference to a national code

Ref country code: SE

Ref legal event code: TRCL

TCNL Nl: translation of patent claims filed
TCAT At: translation of patent claims filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: PP

Ref document number: 20030300027

Country of ref document: GR

DET De: translation of patent claims
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1023333

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1027090

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070317